Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108864 | 0.76 | CA2 (0.61) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL5493642 | 0.73 | CA2 (0.41) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL269050 | 0.72 | ALDH1A1 (0.48) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL31346305 | 0.71 | CA2 (0.55) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL25404425 | 0.69 | — | — | |
| 2-Oxoisohexanoate SCHEMBL43491 | 0.69 | — | — | |
| 2-Oxoisohexanoate SCHEMBL18302256 | 0.69 | CA2 (0.52) | CA2ALDH1A1TDP1CYP2C19CA1 | |
| SCHEMBL7219721 | 0.69 | FFAR3 (0.37) | ALDH1A1TDP1CA1 | |
| SCHEMBL93309 | 0.69 | — | — | |
| 3-Methylbutanoic Acid SCHEMBL8572664 | 0.69 | CA2 (0.88) | CA2ALDH1A1TDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | disclosed |
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3038621-B1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RES INSTITUTE (US) | 2020-12-02 | — | — | EP | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9980964-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-05-29 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-6603007-B1 | Intermediates in the fields of pharmaceuticals, agrichemicals, ligands, silver halide photosensitive materials, liquid crystals, surfactants, electrophotography and organic electroluminescence | SANKIO CHEMICAL CO., LTD. (JP) | 2003-08-05 | — | — | US | disclosed |
| EP-1231207-A1 | NOVEL BIPYRIDYL DERIVATIVES | Sankio Chemical Co., Ltd. (JP) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | CA2 2398/4885ALDH1A1 1461/4885TDP1 4644/4885 |
| US-11596716-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | CA2 2747/4885ALDH1A1 1413/4885TDP1 4775/4885 |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | CA2 3737/4885ALDH1A1 2838/4885TDP1 2390/4885 |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CA2 1797/4885ALDH1A1 4078/4885TDP1 3334/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | CA2 3750/4885ALDH1A1 2289/4885TDP1 2480/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | CA2 1481/4885ALDH1A1 4394/4885TDP1 957/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | CA2 2747/4885ALDH1A1 1413/4885TDP1 4775/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | CA2 3737/4885ALDH1A1 2838/4885TDP1 2390/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | CA2 3737/4885ALDH1A1 2838/4885TDP1 2390/4885 |
| US-20160038641-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | CA2 2171/4885ALDH1A1 1157/4885TDP1 4712/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | CA2 3737/4885ALDH1A1 2838/4885TDP1 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.